Cargando…
Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967174/ https://www.ncbi.nlm.nih.gov/pubmed/35372010 http://dx.doi.org/10.3389/fonc.2022.803454 |
_version_ | 1784678784472973312 |
---|---|
author | Liu, Qin-qin Lin, Hao-ming Han, Hong-wei Yang, Cai-ni Liu, Chao Zhang, Rui |
author_facet | Liu, Qin-qin Lin, Hao-ming Han, Hong-wei Yang, Cai-ni Liu, Chao Zhang, Rui |
author_sort | Liu, Qin-qin |
collection | PubMed |
description | BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case of a 74-year-old male who underwent radical resection of gallbladder carcinoma at a local hospital. Seven months later, he was admitted to our hospital due to right upper abdominal discomfort. Postoperative radiological examinations showed multiple hepatic lesions, hilar lymph node metastasis, and main portal vein tumor thrombus. The pathological consultation results confirmed GBCS and immunohistochemical examinations revealed PD-L1 expression in 20% of tumor cells. Then, the patient received chemotherapy (Gemcitabine plus Oxaliplatin, GEMOX) in combination with anti-PD-1 therapy. After nine courses of the combination therapy, complete regression of the tumors was achieved with no evidence of relapse till now. CONCLUSIONS: We, for the first time, reported a patient with recurrent GBCS who benefited from the combined chemotherapy and immunotherapy, providing a potential effective management strategy for the refractory malignant tumor. |
format | Online Article Text |
id | pubmed-8967174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89671742022-03-31 Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review Liu, Qin-qin Lin, Hao-ming Han, Hong-wei Yang, Cai-ni Liu, Chao Zhang, Rui Front Oncol Oncology BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case of a 74-year-old male who underwent radical resection of gallbladder carcinoma at a local hospital. Seven months later, he was admitted to our hospital due to right upper abdominal discomfort. Postoperative radiological examinations showed multiple hepatic lesions, hilar lymph node metastasis, and main portal vein tumor thrombus. The pathological consultation results confirmed GBCS and immunohistochemical examinations revealed PD-L1 expression in 20% of tumor cells. Then, the patient received chemotherapy (Gemcitabine plus Oxaliplatin, GEMOX) in combination with anti-PD-1 therapy. After nine courses of the combination therapy, complete regression of the tumors was achieved with no evidence of relapse till now. CONCLUSIONS: We, for the first time, reported a patient with recurrent GBCS who benefited from the combined chemotherapy and immunotherapy, providing a potential effective management strategy for the refractory malignant tumor. Frontiers Media S.A. 2022-03-14 /pmc/articles/PMC8967174/ /pubmed/35372010 http://dx.doi.org/10.3389/fonc.2022.803454 Text en Copyright © 2022 Liu, Lin, Han, Yang, Liu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Qin-qin Lin, Hao-ming Han, Hong-wei Yang, Cai-ni Liu, Chao Zhang, Rui Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title | Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title_full | Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title_fullStr | Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title_full_unstemmed | Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title_short | Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review |
title_sort | complete response to combined chemotherapy and anti-pd-1 therapy for recurrent gallbladder carcinosarcoma: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967174/ https://www.ncbi.nlm.nih.gov/pubmed/35372010 http://dx.doi.org/10.3389/fonc.2022.803454 |
work_keys_str_mv | AT liuqinqin completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview AT linhaoming completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview AT hanhongwei completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview AT yangcaini completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview AT liuchao completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview AT zhangrui completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview |